#### 1 Detecting HRD in whole-genome and whole-exome sequenced breast and ovarian

#### 2 cancers

- 3 Ammal Abbasi<sup>1-5</sup>, Christopher D. Steele<sup>1-3</sup>, Erik N. Bergstrom<sup>1-3</sup>, Azhar Khandekar<sup>1-4</sup>,
- 4 Akanksha Farswan<sup>6-7</sup>, Rana R. Mckay<sup>3</sup>, Nischalan Pillay<sup>6-7</sup>, and Ludmil B. Alexandrov<sup>1-5\*</sup>
- 5
- <sup>6</sup> <sup>1</sup>Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, 92093, USA
- <sup>7</sup> <sup>2</sup>Department of Bioengineering, UC San Diego, La Jolla, CA, 92093, USA
- <sup>8</sup> <sup>3</sup>Moores Cancer Center, UC San Diego, La Jolla, CA, 92037, USA
- <sup>9</sup> <sup>4</sup>Bioinformatics and Systems Biology Graduate Program, UC San Diego, La Jolla, CA,
- 10 92093, USA
- <sup>5</sup>Sanford Stem Cell Institute, University of California San Diego, La Jolla, CA 92037
- 12 <sup>6</sup>Research Department of Pathology, Cancer Institute, University College London,
- 13 London, WC1E 6BT, UK
- <sup>14</sup> <sup>7</sup>Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital
- 15 NHS Trust, Stanmore, HA7 4LP, UK
- 16
- <sup>\*</sup>Correspondence should be addressed to <u>L2alexandrov@health.ucsd.edu</u>.
- 18

#### 19 ABSTRACT (147 words)

20 Breast and ovarian cancers harboring homologous recombination deficiency (HRD) are 21 sensitive to PARP inhibitors and platinum chemotherapy. Conventionally, detecting HRD 22 involves screening for defects in BRCA1, BRCA2, and other relevant genes. Recent 23 analyses have shown that HRD cancers exhibit characteristic mutational patterns due to 24 the activities of HRD-associated mutational signatures. At least three machine learning 25 tools exist for detecting HRD based on mutational patterns. Here, using sequencing data 26 from 1,043 breast and 182 ovarian cancers, we trained Homologous Recombination 27 Proficiency Profiler (HRProfiler), a machine learning method for detecting HRD using six 28 mutational features. HRProfiler's performance is assessed against prior approaches 29 using additional independent datasets of 417 breast and 115 ovarian cancers, including 30 retrospective data from a clinical trial involving patients treated with PARP inhibitors. Our 31 results demonstrate that HRProfiler is the only tool that robustly and consistently predicts 32 clinical response from whole-exome sequenced breast and ovarian cancers.

33

#### 34 SIGNIFICANCE (48 words)

35 HRProfiler is a novel machine learning approach that harnesses only six mutational 36 features to detect clinically useful HRD from both whole-genome and whole-exome 37 sequenced breast and ovarian cancers. Our results provide a practical way for detecting 38 HRD and caution against using individual HRD-associated mutational signatures as 39 clinical biomarkers.

### 40 INTRODUCTION

41 Repair of DNA double strand breaks by homologous recombination (HR) is an essential 42 cellular mechanism for maintaining genomic stability and for preventing tumorigenesis 43 (1). Prior studies have elucidated key genes in the HR pathway, including, BRCA1, 44 BRCA2, RAD51, and PALB2, that commonly have pathogenic germline variants and/or 45 somatic mutations in breast and ovarian cancers (1). Defects in HR genes can disable 46 the HR repair pathway making cells vulnerable to double strand breaks and, thus, provide 47 a treatment opportunity. Specifically, patients with cancers harboring defective HR repair 48 are sensitive to both poly (ADP-ribose) polymerase inhibitors (PARPi) and to platinum 49 chemotherapy (2,3).

50

51 Conventional stratification of HR deficient (HRD) and HR proficient (HRP) cancers 52 involves screening for canonical genomic markers, including pathogenic germline 53 variants and somatic copy number alterations in HR genes (4-6). Previous experimental 54 studies (7) and genomics analyses (8) have also revealed that HRD cells exhibit 55 characteristic patterns of somatic mutations due to the activities of HRD-associated 56 mutational processes. Currently, there are at least seven mutational signatures that have 57 been putatively associated with and/or utilized to detect HRD: (i) single base substitution 58 (SBS) signatures SBS3 and SBS8 both characterized by generally flat, yet distinct, 59 profiles (9); (ii) genomic rearrangement signatures RS3 and RS5 reflecting non-clustered 60 tandem duplications and deletion, respectively (10); (iii) small insertions and deletions 61 (ID) signatures ID6 and ID8, predominately encompassing indels at microhomologies

62 (11); and *(iv)* copy number (CN) signature CN17 characterized by large tandem
63 duplications (12).

64

65 At least three machine learning approaches have also been developed to capture HR 66 deficient cancers by examining the patterns of somatic mutations found in cancer 67 genomes: HRDetect (13), CHORD (14), and SigMA (15). HRDetect uses signatures SBS3, SBS8, RS3, RS5, and indels at microhomologies corresponding to ID6 and ID8 to 68 detect HRD in breast cancers (13). CHORD is an alternative pan-cancer HRD prediction 69 70 tool that does not rely on mutational signatures, but it rather uses 29 mutational features 71 directly observed in cancer genomes (14). CHORD is more computationally efficient and 72 prior studies have shown that it has an almost identical performance to the one of 73 HRDetect (13). However, both CHORD and HRDetect use HRD-specific patterns of 74 genomic rearrangements that can be only reliably detected from whole-genome 75 sequencing (WGS) data (13,14). By excluding genomic rearrangements, HRDetect can 76 also be applied to whole-exome sequencing (WES) data, albeit, with significantly 77 diminished performance (13). Conversely, CHORD's implementation does not allow 78 utilizing WES cancers. In contrast to CHORD and HRDetect, SigMA was developed to 79 exclusively detect HRD-associated signature SBS3 from whole-genome, whole-exome, 80 and targeted gene panel sequencing data with SigMA's focus being on panel sequencing 81 data (15). Nevertheless, to be applied to a sample, SigMA requires at least five somatic 82 mutations within the examined cancer (15). Based on Memorial Sloan Kettering Cancer 83 Center's Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) data

(16), this limits SigMA's applicability to approximately 37% of breast and ovarian cancers
profiled with MSK-IMPACT targeted gene panel.

86

87 In this manuscript, we perform retrospective analyses to evaluate the clinical utility of 88 canonical gene-based biomarkers, HRD-associated mutational signatures, and machine 89 learning approaches to detect treatment sensitive breast and ovarian cancers. While the 90 presence of individual HRD-associated mutational signatures are generally ineffective in 91 detecting clinical response, existing machine learning tools can capture treatment 92 sensitivity in WGS cancers but not in WES cancers. To address this limitation, we 93 developed Homologous Recombination Proficiency Profiler (HRProfiler), a machine 94 learning method that harnesses only six mutational features for detecting clinically 95 actionable HRD from both whole-genome and whole-exome sequenced breast and 96 ovarian cancers. Our findings offer a pragmatic approach to detect HRD in WES cancers 97 and underscore the importance of exercising caution when considering individual HRD-98 associated mutational signatures as clinical biomarkers.

#### 100 **RESULTS**

#### 101 Feature engineering and model training of HRProfiler

102 To determine the set of robust HRD-associated mutational patterns that can be detected 103 using WGS and WES cancers, we identified significantly enriched mutation types specific 104 to somatic SBSs (9), IDs (11), and CNs (12). In particular, using previously developed 105 schemas (9,11,12), we compared the types of somatic mutations enriched in HRD or HRP 106 cancers. Comparisons were performed for whole-genome sequenced breast cancers 107 using a subset of the Sanger Institute's 560 breast cancer genomes cohort (10) (Sanger-108 WGS-Breast; Fig. 1a) as well as for whole-exome sequenced breast cancers using a 109 subset of TCGA's breast cancer cohort (17) (TCGA-WES-Breast; Fig. 1b). As previously 110 done (13,14,18) patients were classified as HRD based on a combination of their genomic 111 instability and the presence of pathogenic germline variants, somatic mutations, or 112 methylation of BRCA1 or BRCA2. Feature engineering and the subsequent training of 113 HRProfiler was performed only on the designated training datasets (**Supplementary Fig.** 114 S1).

115

At the SBS resolution, we observed a striking enrichment of C:G>T:A single base substitutions at 5'-NpCpG-3' context (mutated based underlined; N reflects any base) in HRP samples (**Fig. 1***a-b*). This suggests that a relatively large proportion of mutations in HRP samples are C:G>T:A transitions at CpG sites when compared to HRD samples. Conversely, HRD samples were enriched for C:G>G:C single base substitutions at 5'-NpCpT-3' context. At the indel resolution, we observed an enrichment of deletions spanning at least 5 base pairs (bp) with flanking microhomology sequences across HRD

123 samples (Fig. 1a-b). These mutations are known to arise from the erroneous activities of 124 the microhomology-mediated end joining or the single strand annealing DNA repair 125 pathways in the absence of a functional HR pathway (19). At the copy number resolution, 126 Loss of Heterozygosity (LOH) events spanning 1 to 40Mb and heterozygous events 127 spanning 10 to 40Mb with a Total Copy Number (TCN) state between 3 and 9 were 128 enriched in HRD samples (Fig. 1a-b). In contrast, very large (>40Mb) heterozygous 129 segments with TCN between 2 and 4 were enriched in HRP samples (Fig. 1a-b). This 130 finding suggests that very large diploid segments or regions that have undergone 131 genome-doubling are enriched in HRP samples, in line with the observation that HRP 132 samples are genomically stable and harbor relatively low copy number aberrations (18).

133

134 Based on these observations, we combined the mutational channels (Methods) into six 135 genomic features: (i) genomic segments with LOH and sizes between 1 and 40 136 megabases (abbreviated as LOH:1-40Mb); (ii) deletions spanning at least 5bp at 137 microhomologies (DEL.5.MH); (iii) heterozygous genomic segments with TCN between 3 138 and 9 and sizes between 10 and 40 megabases (3-9:HET:10-40Mb); (iv) C:G>G:C 139 substitutions at 5'-NpCpT-3' context (N[C>G]T); (v) C:G>T:A substitutions at 5'-NpCpG-140 3' context (N[C>T]G); and (vi) heterozygous genomic segments with TCN between 2 and 141 4, and sizes above 40 megabases (2-4:HET:>40Mb). To evaluate if these genomic 142 features are sufficient to distinguish HRD and HRP samples, we performed principal 143 component analysis (PCA) using the training data. We observed a separation between 144 HRD from HRP samples across the two principal components for both WGS (Fig. 1c) and 145 WES (Fig. 1d) breast cancers.

146 Next, using the six genomic features, we trained a machine learning tool, HRProfiler, 147 based on a linear kernel support vector machine. HRProfiler comprises WGS and WES 148 models that were trained using 371 samples from the Sanger-WGS-Breast (13) and 672 149 samples from the TCGA-WES-Breast (17) datasets respectively (Supplementary Fig. 150 **S1**). Ten-fold cross validation was conducted to determine the feature weights for the two 151 trained models. As expected, features with positive weights (*i.e.*, LOH:1-40Mb, 152 DEL.5.MH, 3-9:HET:10-40Mb, and N[C>G]T) were enriched in HRD samples, whereas 153 features with negative weights (*i.e.*, N[C>T]G and 2-4:HET:>40Mb) were enriched in HRP 154 samples (Fig. 1e).

155

#### 156 Comparing HRD detection methods in WGS and WES breast cancers

157 In principle, two distinct approaches have been utilized to evaluate the performance of 158 methods for detecting HRD. In their original publications, CHORD and HRDetect have 159 relied on concordance between their predictions and prior HRD genomic annotations 160 (13,14). This concordance can be quantified by area under the receiver operating 161 characteristic curve (AUC) with both CHORD and HRDetect reporting AUCs above 0.90 162 for WGS cancers (13.14). However, this type of comparison requires a ground truth for 163 HRD and HRP cancers which, in most cases, is not straightforward to derive. The second 164 approach relies on comparing clinical endpoints for HRD and HRP predicted cancers in 165 patients treated with either chemotherapy or PARPi. The advantage of this approach is 166 that it could provide immediate clinical relevance. Unfortunately, such comparisons 167 require the availability of well annotated clinico-genomics datasets which are currently

limited especially at the whole-genome resolution. Here, we utilize both approaches toput HRProfiler in the context of previously developed methods.

170

171 To evaluate the performance of HRProfiler, SigMA, HRDetect, and CHORD in the context 172 of HRD genomic ground truth annotations, we applied the four tools to an independent 173 set of 237 whole-genome sequenced triple negative breast cancers (TNBCs) from the 174 Sweden Cancerome Analysis Network – Breast project (SCAN-B; ClinicalTrials.gov 175 identifier NCT02306096) (20) as well as to 71 held-out TCGA breast cancers which have 176 been profiled using both whole-genome and whole-exome sequencing. Additionally, we 177 applied the tools to an independent external WES dataset of 109 MSK-IMPACT breast 178 cancers (21). All tools exhibited good AUC performance when applied to the WGS 179 cancers (Fig. 2a-b; Supplementary Fig. S2a-b) while HRProfiler outperformed 180 HRDetect and SigMA for WES breast cancers (Fig. 2c-d; Supplementary Fig. S2c-d). 181 CHORD could not be applied to WES data. Importantly, HRProfiler was the only tool with 182 AUCs above 0.90 across all WES and WGS breast cancer datasets (Fig. 2).

183

To evaluate the potential clinical utility of HRProfiler, SigMA, HRDetect, and CHORD in serving as predictive biomarkers for adjuvant chemotherapy treated breast cancers, we applied the tools to a subset of 145 whole-genome sequenced chemotherapy-treated TNBCs with information for interval disease-free survival (20). Additionally, the 145 TNBCs were down-sampled to whole-exomes (dWES) to further assess the ability of each tool to predict HRD robustly at both whole-genome and whole-exome resolutions. As

190 previously reported (20), when applied to WGS breast cancers, HRDetect was able to 191 identify 99 HRD samples which exhibited better survival when compared to the 46 HRP 192 samples after adjusting for grade and age at diagnosis (hazard ratio [HR]=0.42; p-193 value=0.020; Fig. 3a). However, the tool exhibited markedly worse sample stratification 194 on the dWES data (HR=0.54; p-value=0.092) with 39 samples (26.9% of all examined 195 TNBCs) being differently annotated when compared to the WGS data. CHORD's 196 performance on WGS samples was very similar to that of HRDetect (Supplementary Fig. S3), however, the tool cannot be applied to the dWES data. Applying SigMA to the 197 198 145 TNBCs did not result in a statistically significant separation for either the WGS breast 199 cancers (p-value=0.068) or the dWES data (p-value=0.94; Fig. 3b). In contrast, 200 HRProfiler was able to better stratify breast cancers from both WGS (HR=0.40; p-201 value=0.021) and dWES data (HR=0.38; p-value=0.02; Fig. 3c). Importantly, only 9 202 samples (6.2% of all examined TNBCs) were differently annotated by HRProfiler when 203 the tool was applied to WGS and dWES data (Fig. 3c). Lastly, partitioning the 145 TNBCs 204 based on the presence of defects in BRCA1/2 or the presence of HRD-associated 205 signatures SBS3 or CN17 did not result in statistically significant separation 206 (Supplementary Fig. S4). Nevertheless, stratifying the 145 TNBCs based on the 207 presence of ID6 was able to separate the breast cancers, but captured 41 fewer HRD 208 patients compared to HRProfiler (HR=0.48; p-value=0.04; **Supplementary Fig. S4**).

209

#### 210 Comparing HRD detection methods in WES ovarian cancers

211 To determine if the breast cancer specific mutational features can be generalized to 212 another HRD-associated cancer, we trained an ovarian-specific whole-exome model using 182 high-grade serous carcinoma from the TCGA-Ovarian-WES dataset (17) 213 214 (Supplementary Fig. S5a). As done for breast cancer, ten-fold cross validation was 215 conducted for HRProfiler to determine the feature weights for the trained whole-exome 216 model. Similar features to the ones observed in breast cancer were enriched in HRD and 217 HRP ovarian cancers (Supplementary Fig. S5b). To examine the performance of 218 HRProfiler, SigMA, and HRDetect in the context of HRD genomic ground truth 219 annotations for whole-exome sequenced ovarian cancer, we applied the three tools to 40 220 held-out TCGA ovarian samples as well as to an independent set of 50 MSK-IMPACT 221 whole-exome sequenced ovarian cancers (21) (Supplementary Fig. S6a-b). For both 222 datasets, HRProfiler outperformed the other two approaches by consistently exhibiting 223 AUCs above 0.90 (Supplementary Fig. S6a-b).

224

225 To assess the clinical utility of HRProfiler, SigMA, and HRDetect to serve as predictors of 226 clinical outcome in ovarian cancer, we examined the progression free survival for an 227 independent set of 25 high-grade ovarian cancers from a phase lb PARPi clinical trial of 228 olaparib in combination with the PI3K inhibitor buparlisib (BKM120; ClinicalTrials.gov 229 identifier NCT01623349) (22). HRProfiler's annotations were able to separate PARPi 230 treated samples based on progression free survival (HR=0.25; p-value=0.037; Fig. 4) 231 with HRDetect also performing relatively well on these data (HR=0.32; p-value=0.056; 232 Fig. 4b). Moreover, partitioning the 25 PARPi-treated ovarian cancers based on the 233 presence of any of the HRD-associated signatures SBS3, CN17, or ID6 did not lead to

- 234 differences in survival endpoints (Supplementary Fig. S7). Lastly, annotating samples
- as HRD and HRP based on defects in *BRCA1/2* genes provided separation in progression
- free survival for the 25 PARPi-treated ovarian cancers (**Supplementary Fig. S7**).

#### 238 **DISCUSSION**

239 There is an increasing momentum in precision oncology towards more comprehensive 240 genomic profiling to identify complex biomarkers like HRD as part of routine clinical care 241 (23). With continuing advances in sequencing technologies and the corresponding 242 exponential decrease in their cost, clinical whole-exome sequencing is becoming 243 increasingly more prevalent (24-26). To harness the clinical utility of whole-exome 244 sequencing for predicting HRD, we present a novel machine learning approach called 245 HRProfiler that utilizes a minimal set of six genomic features to predict HRD across both 246 whole-genome and whole-exome sequenced breast and ovarian cancers. Unlike existing 247 methods that focus solely on mutation types enriched in HRD samples (13-15), HRProfiler 248 incorporates small and large-scale mutational events enriched in both HRD and HRP 249 cancers. HRProfiler also circumvents the need for genomic rearrangements and 250 mutational signature extraction, which can be unreliable especially when using sparse 251 datasets derived from whole-exome sequencing data (11).

252

253 HRProfiler demonstrated comparable performance to existing approaches when applied 254 to whole-genome sequencing data and the tool surpassed other machine learning 255 methods when applied to whole-exome sequenced cancers. The sub-optimal 256 performance of HRDetect on whole-exome sequenced tumors is perhaps unsurprising 257 given that HRDetect was developed for whole-genome sequenced breast cancers and 258 the original publication noted a poor performance for whole-exome sequenced tumors 259 (13). In contrast, despite its tailored design for whole-exome and targeted panel 260 sequencing data, SigMA exhibited comparatively limited performance in our tests. Indeed,

SigMA is a machine learning surrogate for detecting HRD-associated signature SBS3 and our results show that SBS3 alone is not a reliable predictor of survival even when detected by other tools. Similarly, other HRD-associated signatures, such as CN17 and ID6, did not provide consistent clinical separation for breast or ovarian cancers. Overall, these results indicate that the presence of an individual HRD-associated signature in a cancer sample does not necessarily indicate a clinically significant or an actionable event.

267

268 HRProfiler's ability to separate HRD samples sensitive to treatment with PARP inhibitors 269 from whole-exome sequencing data opens additional opportunities for broadening 270 treatment options to a wider patient population. Given the non-tissue-specific nature of 271 the HRD mutational footprint, our six mutational features can be refined in the future to 272 predict HRD status in other HRD-associated cancers, including prostate and pancreatic 273 cancers. Such an effort will ideally require large sets with well annotated clinico-genomics 274 datasets for both cancer types, which, to the best of our knowledge, are currently not 275 available.

276

Although we assessed HRProfiler's performance using independent datasets encompassing 417 breast and 115 ovarian cancers, along with retrospective data from two clinical trials, we recognize the constraints posed by the use of relatively small sample sizes for some of the reported survival analyses. Future large-scale, independent, and purposefully designed clinical trials will be necessary to validate HRProfiler's capacity to serve as a predictive and/or prognostic biomarker for routine clinical decision making. Notwithstanding, HRProfiler provides a crucial link in utilizing the molecular phenotypic

- 284 changes of impaired DNA repair mechanisms for detecting homologous recombination
- 285 deficiency in whole-exome sequenced cancers. Moreover, the tool provides a robust and
- 286 consistent approach that allows detecting whole-exome sequenced cancers that are
- sensitive to PARP inhibitors.

#### 289 METHODS

#### 290 Data sources and pre-processing

In this study, previously published datasets were used for all feature engineering, model development, and validation for both whole-genome sequenced (WGS) and wholeexome sequenced (WES) breast and ovarian cancers.

294 For breast cancer, we downloaded CaVEman mutations and ASCAT allele-specific copy 295 number for 560 Sanger breast cancers (10) from: ftp://ftp.sanger.ac.uk/pub/cancer/Nik-296 ZainalEtAl-560BreastGenomes/. Additional WGS breast cancer datasets used in this 297 study included the 237 Triple Negative Breast (TNBC) samples from the SCAN-B clinical 298 trial (20). CaVEman somatic mutations and ASCAT copy number for the 237 TNBC 299 samples were downloaded from: https://data.mendeley.com/datasets/2mn4ctdpxp/. For 300 the breast cancer WGS dataset from the Pan-Cancer Analysis of Whole Genomes 301 project, consensus somatic mutations and copy number calls were downloaded from the 302 International Consortium's data Cancer Genome portal: 303 https://dcc.icgc.org/releases/PCAWG. For The Cancer Genome Atlas (TCGA) breast 304 cancer WES dataset, the catalogues of somatic mutations and sequencing data were 305 downloaded from the genomics data commons (https://portal.gdc.cancer.gov/) portal and 306 allele-specific whole-exome copy number calls were derived using ASCAT: 307 https://github.com/VanLoo-lab/ascat. For the WES MSK-IMPACT breast cancers, 109 308 whole-exome sequenced breast cancers were downloaded from dbGaP (accession 309 number: phs001783.v1.p1) and processed using an ensemble variant calling pipeline: 310 https://github.com/AlexandrovLab/EnsembleVariantCallingPipeline

311 For ovarian cancer, the WES derived catalogues of somatic mutations and sequencing 312 data from TCGA were downloaded from the genomics data commons portal, and allele-313 specific whole-exome copy number calls were derived using ASCAT. For the ovarian 314 cancer WES MSK-IMPACT dataset, 50 whole-exome sequenced ovarian cancers were 315 downloaded from dbGaP (accession number: phs001783.v1.p1) and processed using the 316 same ensemble variant calling pipeline as the one utilized for breast cancer. Lastly, we 317 downloaded the 25 PARPi treated high-grade ovarian cancers from dbGaP (accession 318 number: phs003019) and processed these data using the ensemble variant calling 319 pipeline.

320

#### 321 Feature engineering for predicting HRD

322 As previously done (13,14,18), a sample with an HRD score of at least 42 for breast 323 cancer (5) and 63 for ovarian cancer (27) or one harboring germline/somatic alterations 324 in BRCA1 or BRCA2 was annotated as homologous recombination deficient (HRD) for all 325 training purposes. All other samples were annotated as homologous recombination 326 proficient (HRP). To identify significantly enriched features in HRD and HRP samples, we 327 generated the average mutational profiles based on proportions across the 96 328 substitution, 83 indel, and 48 copy number mutational contexts. To determine differences 329 in channels at every resolution, we performed Fisher's exact tests to evaluate if there is 330 any statistically significant difference in the average proportion of a given channel 331 between HRD and HRP samples. Significant channels were identified for all types of 332 mutational contexts if their absolute log<sub>2</sub> fold-change (FC) was greater than 0.75 for WGS 333 samples and 0.25 for WES samples, and their  $-\log_{10}(FDR adjusted p-value)$  was greater

334 than 3. Similar workflow was adopted for both whole-genome and whole-exome samples 335 and only channels significantly enriched across both WGS and WES were considered for 336 the feature engineering process. At the single base resolution, A[C>T]G, C[C>T]G, 337 G[C>T]G, and T[C>T]G channels were consistently enriched across HRP samples in both 338 whole-genome and whole-exome datasets. Due to the overlapping/similar mutational 339 context, these four channels were combined into a single feature termed N[C>T]G, where 340 N represents any of the four nucleotide bases (A, C, T, or G). Similarly, A[C>G]T, 341 C[C>G]T, G[C>G]T, and T[C>G]T were channels consistently enriched in HRD samples 342 and were combined into a single feature N[C>G]T. At the indel resolution, 5:Del:M:1, 343 5:Del:M:2, 5:Del:M:3, 5:Del:M:4, and 5:Del:M:5 were significantly enriched channels in 344 HRD samples that represent varying lengths of microhomology sequences at relatively 345 large deletion sites where the length of the deletion is at least 5 base pairs long. These 346 indel channels were combined into a single feature: DEL.5.MH, where DEL.5 presents 347 deletions of length at least 5 bp and MH represent microhomology sequences. At the 348 copy number resolution, multiple significant Loss of Heterozygosity (LOH) events were 349 identified. These events represented LOH segments of at least 1 Mb, where majority of 350 the segment sizes ranged between 1 and 40Mb. These were combined into a single 351 feature LOH:1-40Mb. A similar approach was applied to aggregate significant copy 352 number channels for diploid/genome-doubled copy number segments into a single 353 feature 2-4:HET:>40Mb that accounts for segments with a total copy number state 354 between 2-4 and sizes of at least 40Mb. Lastly, significant copy number channels for 355 amplification events were combined into a single feature: 3-9:HET:10-40Mb, where 3-9

356 represents the segments with a total copy number state of at least 3 and segment sizes357 between 10 to 40Mb.

#### 358 Training and comparing HRD detection methods in WGS cancers

359 To train a model for predicting HRD at WGS resolution, we used samples from the 560 360 Breast dataset. Only 371/560 samples that were labelled as evaluated in the HRDetect 361 publication (13) were considered. The six features derived from the feature engineering 362 step were extracted from the 371 samples and were normalized using StandardScaler in 363 python's sklearn package. The training was based on 371 breast samples, comprising 364 131 HRD and 240 HRP samples, and used a linear kernel support vector machine with 365 L2 regularization. Next, 10-fold cross validation was conducted to tune for hyper-366 parameters and obtain feature weights from the model. To test the model's performance, 367 we predicted HRD probabilities for 71 WGS TCGA breast samples that were sequenced 368 at both whole-genome and whole-exome resolutions. Samples with an HRD probability 369 at least 0.50 were considered as HRD. To validate the model on an external dataset, we 370 predicted HRD probabilities for 237 Triple Negative Breast (TNBC) samples and 371 evaluated its performance against the ground truth. The performance of the model was 372 assessed using machine learning metrics such as sensitivity, precision, and  $F_1$  score. To 373 compare the performance of HRProfiler with other tools, HRD annotations were 374 determined for the 237 TNBC samples using HRDetect, CHORD, and SigMA.

375

#### 376 Training and comparing HRD detection methods in WES cancers

To train a breast cancer specific model for predicting HRD at WES resolution, we used samples from TCGA breast cancer dataset. Only 743 samples that had HRD annotations

379 were used for both training and testing. The six features derived from the feature 380 engineering step were extracted as proportions, except for DEL.5.MH, which was 381 extracted as absolute counts. All features were normalized using StandardScaler in 382 python's sklearn package. The training was based on 672 breast samples that included 383 156 HRD and 516 HRP samples. Next, 10-fold cross validation was conducted to tune 384 for hyper-parameters and obtain feature weights from the model. The model's 385 performance was tested on the held-out 71 breast samples that were previously 386 sequenced at both whole-genome and whole-exome resolution. Samples with an HRD 387 probability at least 0.50 were considered as HRD. To validate the model on an external 388 dataset, we predicted HRD probabilities for 109 MSK-IMPACT breast cancer whole-389 exome sequenced samples and evaluated the model's performance against the ground 390 truth. The performance of the model was assessed using conventional machine learning 391 metrics such as sensitivity, precision, and F<sub>1</sub> score. The WES model was also applied to 392 the down-sampled 237 TNBC samples. The whole-exome features for the 237 TNBC 393 samples were derived by down-sampling the ASCAT copy number calls to segments that 394 spanned the exonic regions. The mutation and indel calls were down-sampled to whole-395 exome resolution using SigProfiler (28). To compare the performance of HRProfiler with 396 other tools, HRD probabilities were also determined for SigMA and HRDetect.

397

To train an ovarian-specific model for predicting HRD at WES resolution, we used samples from the TCGA ovarian dataset. Only 228 samples that had HRD annotations were used for both training and testing. Analogous to training HRProfiler for WES breast cancers, the six features derived from the feature engineering step were extracted as

402 proportions, except for DEL.5.MH, which was extracted as absolute counts. All features 403 were normalized using StandardScaler in the python sklearn package. The training was 404 based on 182 ovarian cancers that comprised of 82 HRD and 100 HRP samples. Next, 405 10-fold cross validation was conducted to tune for hyper-parameters and obtain feature 406 weights from the model. The model's performance was tested on the 39 ovarian cancer 407 that were sequenced at whole-exome resolution. Samples with an HRD probability at 408 least 0.50 were considered as HRD. To validate the model on an external dataset, we 409 predicted HRD probabilities for 50 MSK-IMPACT whole-exome sequenced ovarian 410 cancers and evaluated the model's performance against the ground truth. The 411 performance of the model was assessed using conventional machine learning metrics 412 such as sensitivity, precision, and  $F_1$  score. To compare the performance of HRProfiler 413 with other tools, HRD annotations were determined for the same samples by HRDetect 414 and SigMA using the default breast WGS and ovarian WES pre-trained models, 415 respectively.

416

#### 417 Deriving HRD status based on HRD-associated signatures, genes, and tools

Germline and somatic mutations for *BRCA1* and *BRCA2* and, when available, gene expression and promoter methylation changes in *BRCA1* and *BRCA2* were incorporated for the *BRCA1/2* annotations. Specifically, for TCGA breast cancers, the *BRCA1/2* annotations were derived from Polak *et al.* (29). Conversely, for TCGA ovarian cancers, these annotations were derived from Steele *et al.* (12). For all other datasets, BRCA1/2 annotations were derived from their respective publications.

424

SigprofilerAssigment (v0.1.2) was used to determine the presence of HRD-associated signatures SBS3, ID6, and CN17 (30) using the Catalogue Of Somatic Mutations In Cancer (COSMICv3.4) reference signatures. A sample was classified as HRD positive for a given HRD signature, if it had at least one mutational event attributed to that signature.

430

HRDetect was run using the Signature.tools.lib (v2.3.0) package in R, available at https://github.com/Nik-Zainal-Group/signature.tools.lib. The default HRD probability threshold of 0.70 was employed for predicting HRD status for WGS samples. To execute HRDetect on WES data, we utilized the pre-trained WGS model for prediction. The rearrangement signatures RS3 and RS5, which cannot be derived from WES data, were set to zero, and the default probability threshold of 0.70 was applied for classifying wholeexome sequenced cancers as HRD.

438

CHORD was run using the extractSigsChord function installed from GitHub:
 <a href="https://github.com/UMCUGenetics/CHORD/">https://github.com/UMCUGenetics/CHORD/</a>. It was executed using default settings, and
 a probability threshold of 0.50 was applied for classifying samples as HRD.

442

SigMA (v2.0) was downloaded from GitHub:
<a href="https://github.com/parklab/SigMA/archive/refs/tags/2.0.tar.gz">https://github.com/parklab/SigMA/archive/refs/tags/2.0.tar.gz</a> and it was run using the run
function for signature 3 (also known as SBS3) prediction. For WGS breast datasets, we
used the following parameters when running SigMA: data='wgs', do\_assign=T,
do\_mva=T, tumor\_type='breast', and catalog\_name='cosmic\_v3p2\_inhouse', and we

utilized SigMA strict predictions (pass\_mva\_strict) for our analysis. When running SigMA
on WES datasets, we followed the same procedure as for WGS datasets, except for the
data and tumor\_type parameters. For predicting signature 3 status for TCGA datasets,
the data parameter was set to 'tcga\_mc3', otherwise, it was set to 'seqcap' for all other
WES and down-sampled WES datasets. The tumor\_type parameter was set to 'breast'
for breast and 'ovary' for ovarian whole-exome sequencing data.

454

#### 455 Survival analysis

456 The survival analysis was conducted using the KaplanMeierFitter and CoxPHFitter 457 function from the lifelines package in python (31). Interval disease free survival was used 458 to evaluate patients treated with chemotherapy from the 237 TNBC dataset. Progression 459 free survival endpoint was used to evaluate the survival trends for 25 high-grade ovarian 460 cancer patients treated with PARP inhibitor. P-values and hazard ratios listed in the 461 Kaplan Meier plots are based on the p-values derived from the Cox proportional hazards 462 (coxph) model adjusted by dichotomized age of diagnosis (below and above 50 years 463 old) as well as tumor stage or grade.

464

#### 465 **Statistics**

All statistical analysis were conducted in python using the scikit-learn package. All pvalues were corrected for multiple hypothesis testing using Benjamini-Hochberg procedure, where applicable.

469

470

#### 471 Availability of data and materials

472 HRProfiler is an open-source tool, and it is freely available for academic use as a python
473 package at <a href="https://github.com/AlexandrovLab/HRProfiler">https://github.com/AlexandrovLab/HRProfiler</a>. The pre-trained models for
474 whole-genome and whole-exome sequenced breast and ovarian cancers are provided as
475 part of the tool.

476

#### 477 Competing interests

478 LBA is a co-founder, CSO, scientific advisory member, and consultant for io9, has equity 479 and receives income. The terms of this arrangement have been reviewed and approved 480 by the University of California, San Diego in accordance with its conflict of interest 481 policies. LBA's spouse is an employee of Biotheranostics. ENB is a consultant for io9, 482 has equity, and receives income. AA and LBA declare U.S. provisional patent application 483 filed with UCSD with serial numbers 63/366,392 for detecting homologous recombination 484 deficiency from genomics data. ENB and LBA declare U.S. provisional patent application 485 filed with UCSD with serial numbers 63/269,033 for artificial intelligence architecture for 486 predicting cancer biomarkers, including homologous recombination deficiency. LBA also 487 declares U.S. provisional applications with serial numbers: 63/289,601; 63/483,237; 488 63/412,835; and 63/492,348. All other authors declare that they have no competing 489 interests.

490

#### 491 Funding and acknowledgements

This work was supported by the US National Institute of Health grants R01ES03099301A1, U01DE033345, R01ES032547-01, and R01CA269919-01 to LBA as well as LBA's

Packard Fellowship for Science and Engineering and Cancer Research UK Grand Challenge Award C98/A24032. The research in this grant was also supported by a Curebound Targeted grant to LBA and RRM. The computational analyses reported in this manuscript have utilized the Triton Shared Computing Cluster at the San Diego Supercomputer Center of UC San Diego. The funders had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

500

#### 501 Authors' contributions

AA and LBA designed the overall study. AA performed all analyses with help from CDS, ENB, AK, AF, RRM, NP, and LBA. CDS and AK assisted in the copy number analysis and the feature engineering process. AF contributed to testing the tool's functionality. ENB, RRM, NP, and LBA assisted in the interpretation and analysis of the survival and clinical associations. AA and LBA wrote the manuscript with help and input from all other authors. All authors read and approved the final manuscript.

### 509 **REFERENCES**

- Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous
   Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian
   Cancer. Cancer Discov **2015**;5(11):1137-54 doi 10.1158/2159-8290.CD-15-0714.
- 5132.Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al.514Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian515Cancer. N Engl J Med **2018**;379(26):2495-505 doi 10.1056/NEJMoa1810858.
- 5163.Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al.517Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness518subgroups: the TNT Trial. Nat Med **2018**;24(5):628-37 doi 10.1038/s41591-018-5190009-7.
- 5204.Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, et al. Telomeric allelic521imbalance indicates defective DNA repair and sensitivity to DNA-damaging522agents. Cancer Discov 2012;2(4):366-75 doi 10.1158/2159-8290.CD-11-0206.
- 523 5. Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, *et al.* Homologous 524 Recombination Deficiency (HRD) Score Predicts Response to Platinum-525 Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast 526 Cancer. Clin Cancer Res **2016**;22(15):3764-73 doi 10.1158/1078-0432.CCR-15-527 2477.
- Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, *et al.* Patterns of genomic loss of heterozygosity predict homologous recombination
   repair defects in epithelial ovarian cancer. Br J Cancer **2012**;107(10):1776-82 doi
   10.1038/bjc.2012.451.
- 7. Zamborszky J, Szikriszt B, Gervai JZ, Pipek O, Poti A, Krzystanek M, *et al.* Loss
  of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis
  and has distinct effects on genomic deletions. Oncogene **2017**;36(35):5085-6 doi
  10.1038/onc.2017.213.
- Petljak M, Alexandrov LB, Brammeld JS, Price S, Wedge DC, Grossmann S, *et al.* Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals
   Episodic APOBEC Mutagenesis. Cell **2019**;176(6):1282-94 e20 doi
   10.1016/j.cell.2019.02.012.
- Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al.
  Signatures of mutational processes in human cancer. Nature 2013;500(7463):41521 doi 10.1038/nature12477.
- Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al.
  Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
  Nature 2016;534(7605):47-54 doi 10.1038/nature17676.
- Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, *et al.* The
  repertoire of mutational signatures in human cancer. Nature **2020**;578(7793):94101 doi 10.1038/s41586-020-1943-3.
- 54912.Steele CD, Abbasi A, Islam SMA, Bowes AL, Khandekar A, Haase K, et al.550Signatures of copy number alterations in human cancer. Nature551**2022**;606(7916):984-91 doi 10.1038/s41586-022-04738-6.

- 552 13. Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, *et al.* HRDetect is a
   553 predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat
   554 Med **2017**;23(4):517-25 doi 10.1038/nm.4292.
- 55514.Nguyen L, J WMM, Van Hoeck A, Cuppen E. Pan-cancer landscape of556homologous recombination deficiency. Nat Commun **2020**;11(1):5584 doi55710.1038/s41467-020-19406-4.
- 558 15. Gulhan DC, Lee JJ, Melloni GEM, Cortes-Ciriano I, Park PJ. Detecting the
   559 mutational signature of homologous recombination deficiency in clinical samples.
   560 Nat Genet **2019**;51(5):912-9 doi 10.1038/s41588-019-0390-2.
- 561 16. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, *et al.* Mutational
  562 landscape of metastatic cancer revealed from prospective clinical sequencing of
  563 10,000 patients. Nat Med **2017**;23(6):703-13 doi 10.1038/nm.4333.
- 564 17. Gao GF, Parker JS, Reynolds SM, Silva TC, Wang LB, Zhou W, et al. Before and
  565 After: Comparison of Legacy and Harmonized TCGA Genomic Data Commons'
  566 Data. Cell Syst **2019**;9(1):24-34 e10 doi 10.1016/j.cels.2019.06.006.
- Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, *et al.* Pan cancer analysis of genomic scar signatures associated with homologous
   recombination deficiency suggests novel indications for existing cancer drugs.
   Biomark Res 2015;3:9 doi 10.1186/s40364-015-0033-4.
- Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, *et al.* Clinical
  brca1/2 reversion analysis identifies hotspot mutations and predicted neoantigens
  associated with therapy resistance. Cancer Discovery **2020**;10(10):1475-88 doi
  10.1158/2159-8290.CD-19-1485.
- 575 20. Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reutersward C, Hakkinen J, 576 *et al.* Whole-genome sequencing of triple-negative breast cancers in a population-577 based clinical study. Nat Med **2019**;25(10):1526-33 doi 10.1038/s41591-019-578 0582-4.
- 57921.Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, et580al.TumourlineageshapesBRCA-mediatedphenotypes.Nature5812019;571(7766):576-9 doi 10.1038/s41586-019-1382-1.
- 58222.Batalini F, Gulhan DC, Mao V, Tran A, Polak M, Xiong N, et al. Mutational583Signature 3 Detected from Clinical Panel Sequencing is Associated with584Responses to Olaparib in Breast and Ovarian Cancers. Clin Cancer Res585**2022**;28(21):4714-23 doi 10.1158/1078-0432.CCR-22-0749.
- 58623.Menzel M, Ossowski S, Kral S, Metzger P, Horak P, Marienfeld R, et al. Multicentric587pilot study to standardize clinical whole exome sequencing (WES) for cancer588patients. NPJ Precis Oncol **2023**;7(1):106 doi 10.1038/s41698-023-00457-x.
- Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, *et al.* Wholeexome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded
  tumor samples to guide precision cancer medicine. Nat Med **2014**;20(6):682-8 doi
  10.1038/nm.3559.
- 593 25. Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hullein J, et al.
  594 Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic
  595 Decisions in Patients with Rare Cancers. Cancer Discov 2021;11(11):2780-95 doi
  596 10.1158/2159-8290.CD-21-0126.

- 597 26. Niguidula N, Alamillo C, Shahmirzadi Mowlavi L, Powis Z, Cohen JS, Farwell 598 Hagman KD. Clinical whole-exome sequencing results impact medical 599 management. Mol Genet Genomic Med 2018;6(6):1068-78 doi 600 10.1002/mgg3.484.
- Takaya H, Nakai H, Takamatsu S, Mandai M, Matsumura N. Homologous
  recombination deficiency status-based classification of high-grade serous ovarian
  carcinoma. Sci Rep **2020**;10(1):2757 doi 10.1038/s41598-020-59671-3.
- Bergstrom EN, Huang MN, Mahto U, Barnes M, Stratton MR, Rozen SG, et al.
  SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small
  mutational events. BMC Genomics 2019;20(1):685 doi 10.1186/s12864-019-60412.
- Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, et al. A
  mutational signature reveals alterations underlying deficient homologous
  recombination repair in breast cancer. Nat Genet **2017**;49(10):1476-86 doi
  10.1038/ng.3934.
- 61230.Diaz-Gay M, Vangara R, Barnes M, Wang X, Islam SMA, Vermes I, et al. Assigning613mutational signatures to individual samples and individual somatic mutations with614SigProfilerAssignment.61510.1093/bioinformatics/btad756.
- 61631.Davidson-Pilon C. lifelines: survival analysis in Python. Journal of Open Source617Software **2019**;4(40) doi 10.21105/joss.01317.

#### 619 **FIGURE LEGENDS**

620 Figure 1: Feature engineering to identify significantly enriched somatic mutational 621 features across HRD and HRP breast cancers. (a-b) Volcano plots with log<sub>2</sub> fold 622 change (FC) enrichments across the average proportions of somatic mutations for 96 623 substitution, 83 indel, and 48 copy number mutational channels between homologous 624 recombination deficient (HRD) and homologous recombination proficient (HRP) cancers 625 for 371 Sanger-WGS-Breast (a) and 672 TCGA-WES-Breast samples (b). Channels with 626 an absolute FC greater than 0.75 for WGS and 0.25 for WES, and a -log<sub>10</sub> FDR adjusted 627 p-value greater than 3 are colored. Channels colored in red are enriched in HRD samples, 628 while channels highlighted in blue are enriched in HRP samples. (c-d) Principal 629 component (PC) analysis highlights the relevance of the features derived from the 630 significant channels in (a-b) by separating HRD from HRP samples across the 371 631 Sanger-WGS-Breast (c) and 672 TCGA-WES-Breast cohorts (d). (e) The average 10-fold 632 cross validation weights of the six features derived from the WGS and WES breast 633 training datasets using a linear-kernel support vector machine. Positive weights reflect 634 features predictive for HRD samples, while negative weights correspond to features 635 predictive for HRP samples.

636

Figure 2: Performance of HRD tools on external validation datasets using HRD
genomic ground truth annotations. Receiver operating characteristic curves (ROCs)
were derived for HRProfiler, SigMA, HRDetect, and CHORD. Areas under the ROCs
(AUCs) were calculated for each tool and shown in the legends of the respective panels.
(a) ROCs for 237 whole-genome sequenced (WGS) triple negative breast cancers. (b)

ROCs for 71 WGS TCGA breast cancers. *(c)* ROCs for 71 whole-exome sequenced (WES) breast cancers. *(d)* ROCs for 109 WES MSK-IMPACT breast cancers. No ROCs are shown for CHORD in panels *(c)* and *(d)* as the tool cannot be applied to WES data. In all plots, the x-axes reflect the false positive rates while the y-axes correspond to the true positive rates. Precision and recall curves for the same samples are provided in **Supplementary Figure S2**.

648

649 Figure 3: Predicting survival in breast cancers treated with chemotherapy by HRD 650 tools. Kaplan-Meier curves and confusion matrices for samples predicted as HRD and 651 HRP by (a) HRDetect, (b) SigMA, and (c) HRProfiler in 145 chemotherapy-treated triple 652 negative breast cancers. In each panel, the left plot reflects the Kaplan-Meier curves for 653 whole-genome sequenced breast cancers (WGS). The middle plot corresponds to the 654 Kaplan-Meier curves for the same samples when down-sampled to whole-exomes 655 (dWESs). The right plot contains a confusion matrix that provides a comparison of each 656 tool's HRD annotations from WGS and dWES data. The y-axes on all Kaplan-Meier 657 curves reflect Interval Disease Free Survival (IDFS), and the x-axes correspond to time 658 measured in years. Listed p-values and hazard ratios (HRs) are based on a Cox 659 proportional hazards model after adjusting for age at diagnosis and tumor grade. 95% 660 confidence intervals are provided for all HRs within the Kaplan-Meier plots. The 661 performance of CHORD on WGS data, which was almost identical to the one of 662 HRDetect, can be found in **Supplementary Figure S3**. Comparisons of the clinical utility 663 of BRCA1/2 defects and HRD-associated signatures SBS3, CN17, and ID6 for the same 664 patients are provided in **Supplementary Figure S4**.

#### 665 Figure 4: Predicting survival in ovarian cancers treated PARP inhibitor by HRD

tools. Kaplan-Meier curves for progression free survival (PFS) across 25 PARP inhibitor treated patients with high-grade serous ovarian cancer. Patients are annotated as HRD or HRP based on the predictions from HRProfiler (*left panel*), SigMA (*middle panel*), and HRDetect (*right panel*). Listed p-values and hazard ratios (HRs) are based on a Cox proportional hazards model after adjusting for age at diagnosis and tumor stage. 95% confidence intervals are provided for all HRs within the Kaplan-Meier plots. Comparisons of the clinical utility of BRCA1/2 defects and HRD-associated signatures SBS3, CN17,

and ID6 for the same patients are provided in **Supplementary Figure S7**.

HRP

HRD

PC1(45%)

It is made available under a CC-BY 4.0 International license.



HRD

PC1(39%)

HRP





### b. 71 WGS TCGA Breast Cancers 1.0 0.8 Rate 0.6 Positive 0.4 True 0.2 HRProfiler (AUC = 0.91) —— SigMA (AUC = 0.80) HRDetect (AUC = 0.82) 0.0 ------ CHORD (AUC = 0.80) 0.0 0.2 0.6 0.4 8.0 1.0

False Positive Rate





### a.



### **HRProfiler**



